急性髓系白血病细胞粘附分子VLA-4、LFA-1表达特点及临床意义  

Study on the Expression of Adhesion Molecule VLA-4,LFA-1 in Acute Myeloid Leukemia:the Feature of Expression and Its Clinical Implications

作　　者：刘廷析[1] 刘秀芳[1] 邹萍[1] 向建平[1] 陈燕[1] 喻东姣[1] 李崇渔[1] 

机构地区：[1]同济医科大学血液病学研究所,武汉430022

出　　处：《临床血液学杂志》1997年第4期152-154,共3页Journal of Clinical Hematology

摘　　要：为探讨急性髓系白血病（AML）细胞细胞粘附分子VLA－4、LFA－1表达的临床意义，用免疫组织化学APAAP方法检测50例AML患者白血病细胞VLA－4、LFA－1表达，结合临床资料及化疗疗效分析，发现：①AML细胞VLA－4、LFA－1表达具有很大差异，前者为0％～99％，平均41±31％；后者为1％～100％，平均57±32％。50例AML中VLA－4+病例36例（＜72．0％）；LFA－1+病例37例（74．0％）。②VLA－4+、LFA－1+组与VLA－4-、LFA－1-组在FAB分型、年龄、性别、血红蛋白量、血小板计数、补周血原始细胞数等方面无显著区别。③AML未缓解组VLA－4表达显著高于完全缓解组（56±22％VS20±18％，P＜0．001）；LFA－1表达未缓解组也高于完全缓解组（59±31％VS36±26％，P＜0．05）。复发组VLA－4表达显著高于初发组（54±23％VS34±29％，P＜0．02）；LFA－1表达在复发组有增高趋势（60±33％VS41±32％，P＞0．05），结果表明，VLA－4＋、LFA－1＋、AML细胞具有化疗抵抗特征，可作为AML患者不良预后预测指标之一。The profile of the adhesion molecule VLA-1/LFA-1 expression in 50 patients with acute myeloid leukemia (AML) was determined by APAAP method and the relationship between these antigen expression and the clinical characteristics was discussed. The results showed that the rate of VLA-4 expression in AML cells ranged from 1%~ 99% (mean 41± 31%), 36 of the 50 patients (72. 0%) were VLA-4 positive; LFA-1 expression ranged from 1 % ~ 100% (mean 57±32 % ), 37of the 50 patients (74%) were LFA-1 positive. No significant relationship was observed between these antigen expression and FAB subtype, HB concetration percentage of bone marrow/peripheral blood leukemic cells. The rate of VLA-4 expression in complete remission group was much higher than that in non-remission group(P <0.001) and LFA-1 expression was also higher in CR group than that in non-remission group (P <0.05). The relapsed patients showed markedly higher VLA-4 expression than that in patients at diagnosis (P <0.01 ), while there was trend for LFA-1 expression. The study indicated that AML cells were heterogeneous in the expression of VLA-4/LFA-1, and that measuring of VLA-4/ LFA-1 antigen might be a predictor of poor prognosis.

关 键 词：白血病 髓系 急性 粘附分子 预后 药物疗法 

分 类 号：R733.710.5[医药卫生—肿瘤]